Current news and events

Olweus interviewed by Apollon about OUTSOURCE immunotherapy project

Johanna Olweus (photo: Ola Sæther, Apollon)
Johanna Olweus (photo: Ola Sæther, Apollon)

Professor Johanna Olweus from the Department of Cancer Immunology was in 2019 awarded the ERC Consolidator Grant of 20 mill NOK for the immunotherapy project "OUTSOURCE: Outsourcing cancer immunity to healthy donors". 
The OUTSOURCE project has just started, and on that occacsion Olweus has recently been interviewed by the UiO magazine Apollon on how her group of 15 over the next five years will take their research a long step further towards the clinic, how immune cells from healthy individuals can be the new immune cure for cancer, and how this treatment can kill cancer cells without destroying neighbouring cells. 

How can researchers at UiO and OUS publish openly and free of charge?

From 1 January 2021, publicly funded research must be openly available. The Publish and Read agreements make it possible for researchers to publish openly and at the same time completely free of charge. 
The Open Access team at the University of Oslo Library answers the researchers most frequently asked questions.

Daniel Kalvø and Stine Marie Brasjø during Open Access week 2019. (Photo: Nikolai Vågnes / UiO)

 

 

 

Dr Ragnar Mørk´s Prize for excellent cancer research 2020 to Theo Theodossiou

Theodossis Theodossiou
Theodossis Theodossiou

Dr. Theo Theodossiou at Department of Radiation Biology, Institute for Cancer Research, received Dr. Ragnar Mørk´s Prize for excellent cancer research in the auditorium of Institute for Cancer Research. Theodossiou received the prize for his research on photosensitizers in selective killing of cancer cells. His innovative research includes luminescence-based photosensitizer activation for killing of brain tumours, and proton-induced photosensitizer activation (proton-dynamic therapy) as a novel way of combining proton therapy with photodynamic therapy.

Clinical trials and research projects at Oslo University Hospital related to patients with COVID-19 and SARS CoV-2 infection

On this web page you will find an overview over planned and ongoing clinical trials and other research projects at Oslo University Hospital related to COVID-19 and SARS CoV-2 infection. The information has been retrieved from applications to the regional ethics committee, the Norwegian Research Council, other funding sources, or directly from the researchers behind the projects.

Cell biologists and biophysicists join forces to bend biological membranes

The two research teams with the shared first authors in the front.
The two research teams with the shared first authors in the front.
An interdisciplinary team involving the groups of Harald Stenmark, Institute for Cancer research and Centre for Cancer Cell Reprogramming and Andreas Carlson from the Department of Mathematics, UiO, has unraveled how the ESCRT machinery bends membranes.
An article summarizing the findings was published 2nd of November in the prestigious journal PNAS (Proceedings of the National Academy of Sciences of the United States of America), in an article entitled "Protein crowding mediates membrane remodeling in upstream ESCRT-induced formation of intraluminal vesicles".

Oslo University Hospital and the Norwegian Institute for Public Health to co-lead international collaboration on clinical trials for Covid-19 and future pandemics

OUS scientists involved: Inge C. Olsen and Andreas Barratt-Due (top), Marius Trøseid and Victoria C. Simensen (bottom)
OUS scientists involved: Inge C. Olsen and Andreas Barratt-Due (top), Marius Trøseid and Victoria C. Simensen (bottom)

The Covid-19 pandemic has highlighted the need for rapid and safe testing of agents to treat a high number of SARS-CoV2 infected patients globally. Oslo University Hospital will, together with The Norwegian Institute for Public Health, take part in an ambitious European initiative sponsored by the EU. The project seeks to develop a common platform for clinical trials drawing on expertise from leading hospitals, universities, and research institutions across Europe. 

ERA PerMed grant awarded to European consortium led by Sigrid S. Skånland

Sigrid S. Skånland
Sigrid S. Skånland

A European consortium coordinated by Sigrid S. Skånland, researcher at the Department of Cancer Immunology, was awarded the ERA PerMed grant cofunded by the European Commission for their project “CLL-CLUE: Tailoring the targeted treatment of chronic lymphocytic leukemia”.

ERA PerMed is a new ERA-Net Cofund aiming to promote excellence and reinforce the competitiveness of European players in precision medicine. 

A novel biomedical technology that enhances half-life and mucosal delivery

Members of the Laboratory of Adaptive Immunity and Homeostasis
Members of the Laboratory of Adaptive Immunity and Homeostasis

Ideally, protein-based biologics could be given transmucosally, rather than intravenously or subcutaneously, but the efficiency of transmucosal drug uptake is poor. In addition, many protein-based biologics hamper from short plasma half-life. 

Scientists at University of Oslo and Oslo University Hospital, in collaboration with international researchers in Italy, Germany and US, have developed a biomedical technology that solves these major challenges.

ERGO research presented at an open public meeting at Litteraturhuset

ERGO - Epilepsy Research Group of Oslo - presented their research at an open public meeting in September during the "Forskningsdagene 2020". Title of the meeting was: "Epilepsy - from basic research to modern clinical treatment".
Senior consultant, MD, PhD Kjell Heuser, discussed the role of glial cells in epilepsy. Thereafter, the PhD candidates Toni Berger, Cecilie Bugge Bakketun and Monika Mochol talked about epigentics in epilepsy (TB), how to use brain slices in the study of epilepsy (CBB) and the use of zebrafish in epilepsy research (MM) to understand basic mechanisms of epileptogenesis. 


More news from the archive